Medication Exposure in Pregnancy Risk Evaluation Program.

Area of Science:

• Pharmacovigilance
• Reproductive Health
• Public Health

Background:

• Medication use during pregnancy presents challenges for safety evaluation.
• Existing data limitations hinder comprehensive analysis of drug exposure and outcomes.
• A need exists for large-scale, multi-site research to address these gaps.

Purpose of the Study:

• To describe the Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP).
• To establish a collaborative research framework for studying medication safety in pregnancy.
• To create robust datasets for analyzing medication use and pregnancy outcomes.

Main Methods:

• Multi-site collaborative research program involving the U.S. FDA and multiple research institutions.
• Creation of linked healthcare and birth certificate datasets for over 1.2 million births (2001-2008).
• Inclusion of maternal/infant characteristics, medication use, and medical care data from 11 health plans across 9 states.

Main Results:

• The MEPREP program encompasses data for 1,221,156 children and 933,917 mothers.
• Current studies focus on medication use patterns and data validation.
• The program supports diverse research on medication safety in a large, representative population.

Conclusions:

• MEPREP provides a valuable resource for evaluating medication safety during pregnancy.
• The program's infrastructure enables large-scale studies on diverse populations.
• This collaborative effort enhances understanding of medication risks and benefits in pregnancy.